Tower Research Capital LLC (Trc) Bei Gene, Ltd. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 6,883 shares of BGNE stock, worth $1.56 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
6,883
Previous 1,391
394.82%
Holding current value
$1.56 Million
Previous $312,000
307.37%
% of portfolio
0.03%
Previous 0.01%
Shares
29 transactions
Others Institutions Holding BGNE
# of Institutions
254Shares Held
42.4MCall Options Held
135KPut Options Held
111K-
Baker Bros. Advisors LP New York, NY9.53MShares$2.16 Billion19.52% of portfolio
-
Capital International Investors Los Angeles, CA6.11MShares$1.39 Billion0.22% of portfolio
-
Primecap Management CO Pasadena, CA5.1MShares$1.16 Billion0.74% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E93.8MShares$862 Million26.88% of portfolio
-
Baillie Gifford & CO3.67MShares$832 Million0.54% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...